Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/58775
Type: | Journal article |
Title: | Incretin-based therapies: New treatments for type 2 diabetes in the new millennium |
Author: | Khoo, J. Rayner, C. Jones, K. Horowitz, M. |
Citation: | Therapeutics and Clinical Risk Management, 2009; 5(1):683-698 |
Publisher: | Dove Medical Press Ltd. |
Issue Date: | 2009 |
ISSN: | 1176-6336 1178-203X |
Statement of Responsibility: | Joan Khoo, Christopher K Rayner, Karen L Jones, and Michael Horowitz |
Abstract: | The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP-1 agonists, and rarely with DPP-4 inhibitors, but are dose-dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP-1 agonists and DPP-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin-based therapies also improve quality of life in patients with type 2 diabetes, and may be cost-effective in the long term. |
Keywords: | incretin type 2 diabetes therapy GLP‑1 DPP‑4 |
Rights: | © 2009 Khoo et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
Published version: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731024/pdf/tcrm-5-683.pdf |
Appears in Collections: | Aurora harvest 5 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.